IOBT (IO Biotech) Debt-to-Equity : 0.03 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is IO Biotech Debt-to-Equity?

IO Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.69 Mil. IO Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.33 Mil. IO Biotech's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $72.57 Mil. IO Biotech's debt to equity for the quarter that ended in Sep. 2024 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for IO Biotech's Debt-to-Equity or its related term are showing as below:

IOBT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.37 Med: 0.02 Max: 0.03
Current: 0.03

During the past 5 years, the highest Debt-to-Equity Ratio of IO Biotech was 0.03. The lowest was -0.37. And the median was 0.02.

IOBT's Debt-to-Equity is ranked better than
80.84% of 1023 companies
in the Biotechnology industry
Industry Median: 0.14 vs IOBT: 0.03

IO Biotech Debt-to-Equity Historical Data

The historical data trend for IO Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IO Biotech Debt-to-Equity Chart

IO Biotech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.37

0.02

IO Biotech Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial														0.02	0.02	0.02	0.02	0.03

Competitive Comparison of IO Biotech's Debt-to-Equity

For the Biotechnology subindustry, IO Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IO Biotech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IO Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where IO Biotech's Debt-to-Equity falls into.

IO Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

IO Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.655	+	1.839)	/	133.162
	=	0.02

IO Biotech's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.694	+	1.325)	/	72.565
	=	0.03

IO Biotech (NAS:IOBT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

IO Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of IO Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

IO Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IO Biotech Inc (NAS:IOBT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200

Website

https://www.iobiotech.com

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Executives

Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Brian Burkavage	officer: Chief Accounting Officer	C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Heidi Hunter	director	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Partners Kurma	10 percent owner	24 RUE ROYALE, PARIS I0 75008
Vivo Opportunity Fund Holdings, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Devin Whittemore Smith	officer: General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Vivo Capital Fund Ix, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Qasim Iftikhar Ahmad	officer: Chief Medical Officer	1209 ORANGE STREET, WILMINGTON DE 19801
Amy Sullivan	officer: Chief Financial Officer	38 OUTLOOK ROAD, SWAMPSCOTT MA 01907
David V Smith	director	6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Lundbeckfond Invest A/s	10 percent owner	SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Jack Nielsen	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vanessa Malier	director	1209 ORANGE STREET, WILLMINGTON DE 19801
Claus A. Andersson	director	1209 ORANGE STREET, WILMINGTON DE 19801